Online inquiry

IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13642MR)

This product GTTS-WQ13642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF4 gene. The antibody can be applied in Allergic asthma, Allergic rhinitis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001297562.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7292
UniProt ID P23510
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6668MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ10876MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ1952MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ2748MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ1212MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ2862MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ8667MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ14198MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW